Alexion Pharmaceuticals, Inc. (ALXN)
ALXN Stock Price Chart
|Net Income (ttm)||956.60M|
|Trading Day||December 4|
|Day's Range||120.30 - 121.44|
|52-Week Range||75.56 - 127.81|
ALXN Stock News
Polaris Capital Management leader Bernard Horn (Trades, Portfolio) released his third-quarter portfolio earlier this week.
These two biotech companies are safe bargains in today's volatile market.
These value stocks could be the prime beneficiaries of a young but thriving bull market.
The short interest data are out for November 13, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big p...
Alexion's (ALXN) new 100 mg/mL intravenous (IV) formulation of Ultomiris gets EC approval for PNH and aHUS.
Alexion Receives Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
BOSTON--(BUSINESS WIRE)--Marketing Authorization from European Commission for New Formulation of ULTOMIRIS® (ravulizumab) with Significantly Reduced Infusion Time
Value investors, get those shopping carts ready.
These stocks can bring investors substantial returns for many years to come.
These companies are devoted to helping patients who don't have any other options.
Let's see if Alexion Pharmaceuticals, Inc. (ALXN) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top p...
Owning innovative companies with clear-cut competitive advantages is a recipe for wealth creation.
The best biotech companies to invest in tend to have a commonality: a strong streak of earnings growth. The post These Red-Hot Biotechs Are Leading The Pack And Could Be Actionable appeared fi...
BOSTON--(BUSINESS WIRE)--Alexion to Present at Upcoming Virtual Investor Conferences
Alexion Pharmaceuticals sees its Relative Strength Rating enter the 80-plus level. The post Stock Upgrades: Alexion Pharmaceuticals Shows Rising Relative Strength appeared first on Investor's ...
Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition
BOSTON--(BUSINESS WIRE)--Alexion Announces Upcoming Data Presentations at the 62nd American Society of Hematology Annual Meeting and Exposition
A falling market represents the perfect opportunity to buy into these game-changing companies.
The biotech delivered strong top- and bottom-line growth and boosted its full-year outlook.
Alexion Pharmaceuticals' (ALXN) CEO Ludwig Hantson on Q3 2020 Results - Earnings Call Transcript
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during its third quarter of fiscal 2020, which ended on Sept. 30.
Alexion (ALXN) beats earnings and sales estimates in the third quarter of 2020.
Alexion (ALXN) delivered earnings and revenue surprises of 25.10% and 11.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Shares of Alexion Pharmaceuticals (NASDAQ:ALXN) moved higher by 6.7% in pre-market trading after the company reported Q3 results.
Alexion Pharmaceuticals earnings and revenue easily beat Q3 views. The biotech giant also raised full-year guidance, after saying it would.
BOSTON--(BUSINESS WIRE)--Alexion Reports Third Quarter 2020 Results
The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) disclosed its portfolio for the third quarter of the year earlier this week.
Alexion (ALXN) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
These two rare-disease drug developers are experts at penetrating their markets.
The short interest data are out for October 15, the most recent settlement date. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big po...
These two companies are well-positioned to deliver market-beating returns for years to come.
Alexion (ALXN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alexion (ALXN) will provide updates on its marketed drugs, earnings and other pipeline candidates when it releases third-quarter 2020 results on Oct 29.
BOSTON--(BUSINESS WIRE)--Alexion to Report Third Quarter 2020 Results on Thursday, October 29, 2020
The health care strategy analyst at Jefferies said he expects to see acquisitions in the pharma and biotech space in the $5 billion to $10 billion range, according to an article in FierceBiote...
Earnings season is upon us and investors are pining for information about which stocks and sectors will do well.
With a strong grip on its target markets and a promising pipeline, this company should continue to grow.
Alexion (ALXN) gets FDA approval for Ultomiris 100 mg/mL, a new advanced formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.
The short interest data are out for September 30, the most recent settlement date.
Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time
BOSTON--(BUSINESS WIRE)--Alexion Receives FDA Approval for New Advanced Formulation of ULTOMIRIS® (ravulizumab-cwvz) with Significantly Reduced Infusion Time
Alexion Announces Upcoming Data Presentations at the American Society of Nephrology’s Virtual Kidney Week 2020
BOSTON--(BUSINESS WIRE)--Alexion Announces Upcoming Data Presentations at the American Society of Nephrology’s Virtual Kidney Week 2020
With earnings season about to kick off, investors are being forced into a different sort of earnings season.
Alexion (ALXN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Alexion (ALXN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Alexion (ALXN) announces plans to increase its 2020 sales guidance by more than $200 million and buy back $3 billion of stock.
Drug developers don't get much cheaper than this.
Alexion Pharmaceuticals: More Potential Ahead Despite Upbeat Guidance
Announcements that Alexion Pharmaceuticals Inc. (NASDAQ: ALXN) made at its virtual Investor Day about expanding its pipeline and its guidance led to a handy gain in its shares on Tuesday.
Alexion Pharmaceuticals, citing a 'robust pipeline' across seven rare disease franchises, said ahead of its Virtual Investor Day that it expects to hike its sales guidance; ALXN stock rose. Th...
Alexion's stock rises after upbeat revenue outlook, plan to buy back at least $3 billion in stock through 2023
Shares of Alexion Pharmaceuticals Inc. ALXN, +3.31% rose 1.5% in premarket trading Tuesday, after the biopharmaceutical company said it expects to raise its 2020 revenue guidance by more than ...
Alexion Highlights Promising Pipeline & Distinguished Rare Disease Capabilities at Virtual Investor Day
BOSTON--(BUSINESS WIRE)--Alexion Highlights Promising Pipeline & Distinguished Rare Disease Capabilities at Virtual Investor Day
Their addressable markets may be small, but that doesn't mean developers will fail to profit from these boundary-breaking drugs.
Alexion Pharmaceuticals develops and commercializes various therapeutic products. The company offers ULTOMIRIS (ALXN1210/ravulizumab-cwvz), a C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS); and SOLIRIS (eculizumab), a monoclonal antibody for the treatment of PNH, aHUS, generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia;... [Read more...]
|IPO Date |
Feb 28, 1996
|Stock Exchange |
|Ticker Symbol |
In 2019, ALXN's revenue was $4.99 billion, an increase of 20.81% compared to the previous year's $4.13 billion. Earnings were $2.40 billion, an increase of 2,998.32%.
According to 25 analysts, the average rating for ALXN stock is "Buy." The 12-month stock price forecast is 145.35, which is an increase of 20.18% from the latest price.